|Articles|February 8, 2004

Enbrel manufacturer speaks of post-approval plan

Washington, D.C. ­­ Officials of Amgen spoke of teaching patientsabout biologic treatments of psoriasis, dermatologists spreading the wordabout the new class of drugs, and the physician-patient relationship asits Enbrel (etanercept) added to the resume leading it toward approval bythe U.S. Food and Drug Administration.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME